Noxopharm (ASX: NOX) has made ‘substantial progress’ with its Chroma technology platform, reporting encouraging brain cancer results and early work on leukaemia.
The Chroma drug development program focuses on generating first-in-class novel cancer treatment options in areas of substantial unmet need to create future commercial opportunities for the company.
Glioblastoma – a lethal and incurable disease with limited treatment options that accounts for 66% of all Australian brain cancer diagnoses and has a median survival time of 15 months after diagnosis – is one such area, with a global market worth around US$2.9 billion in 2022 and forecast to grow at an annual rate of 8.8%.
Research grant
Noxopharm and the University of South Australia received a $100,000 grant from cancer research organisation Tour de Cure in April to conduct pre-clinical work on CRO-70 and CRO-71, drugs developed on the Chroma platform that have since been tested on an extensive biobank of patient-derived tumour explant organoids (GBOs), a state-of-the-art glioblastoma model established by researchers at the university’s Centre for Cancer Biology.
GBOs are generated from tumours surgically excised from actual brain cancer patients, maintaining the three-dimensional architecture and complex microenvironment composition of human brain tumours and providing a realistic environment for drug testing.
Noxopharm reported that the drugs had significantly reduced the growth of these glioblastoma explants by an average in excess of of 75% compared to untreated controls, with preliminary analysis also showing each could cross the blood-brain barrier, an important protective filter for the brain that most drugs do not manage to penetrate.
Early animal studies resulted in a favourable safety and toxicity profile for both drugs that will be further investigated over the coming months.
Gene mutation
Noxopharm has also identified a novel drug to target a gene mutation found in acute myeloid leukaemia (AML) that arises during current treatment options and becomes resistant to standard-of-care drugs.
There is a significant need to develop new treatments for AML, particularly those targeting cancerous leukaemic cells while sparing non-cancerous healthy cells.
Early findings show the Chroma candidate can overcome drug resistance and help prevent the cancer from returning aggressively after initial treatment.
AML is a type of blood cancer that represents around 40% of all new adult-onset leukaemias in Australia and was the leading cause of leukaemia-related deaths in 2020.
It has a median overall survival rate of around 25% five years after diagnosis and an incidence rate of approximately 20 people per 100,000 in Australians over 65 years of age.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.